1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Tesaro Shakes Up EU PARP Market With Zejula Launches

 
• By Alexandra Shimmings

EU approval signals the start of a marketing push against the combined might of AstraZeneca and Merck & Co – Tesaro believes it has the label to set it apart. For now, at least.

Michelangelo's David
Michaelangelo depicts David about to go into battle against Goliath • Source: Shutterstock

Launches of Zejula (niraparib) in its first European markets of Germany and the UK are expected in December, now that it has been granted approval by the EMA, as Tesaro Inc. mounts its challenge to AstraZeneca PLC 's Lynparza (olaparib) and seeks to establish its own position ahead of likely approval of another PARP inhibitor, Clovis Oncology Inc.'s Rubraca (rucaparib).

The three PARP inhibitors are jockeying for position in both the US and EU in the fast-moving ovarian cancer market, where their respective indications – and indication expansions – have a huge impact on commercial performance

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.